Locus + J&J
Johnson & Johnson has invested $20 million (with another ~$800 million to follow if things go well) into Locus Biosciences, a biotech company equipping phages with CRISPR-Cas3 to obliterate bacterial DNA upon phage infection.
Topics
Johnson & Johnson has invested $20 million (with another ~$800 million to follow if things go well) into Locus Biosciences, a biotech company equipping phages with CRISPR-Cas3 to obliterate bacterial DNA upon phage infection.